Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Relay Therapeutics (United States) | Researchclopedia

Back to institutions

Relay Therapeutics (United States)

Cambridge, Massachusettscompany

308

Works

20,481

Citations

74

h-index

Top Research Topics

Computational Drug Discovery Methods Machine Learning in Materials Science Protein Structure and Dynamics

Top Researchers

G. Chiarelli Relay Therapeutics (United States)

1,803 works78,453 citationsh-index: 123

Recent Research

Nanoscale direct-to-biology optimization of Cdk2 inhibitors

James L. Douthwaite,Damian J. Houde,et al.

20260 citations

Smart Grid and Power Systems

Power Systems and Technologies

Chemical Synthesis and Analysis

Genetics, Bioinformatics, and Biomedical Research

Fibroblast Growth Factor Research

Power Systems Fault Detection

RNA and protein synthesis mechanisms

Enzyme Structure and Function

Advanced Computational Techniques and Applications

Michael Gnant Comprehensive Cancer Center Vienna

1,096 works77,885 citationsh-index: 102

Scott F. Anderson University of Washington

507 works67,612 citationsh-index: 89

Nicholas C. Turner Institute of Cancer Research

1,155 works44,942 citationsh-index: 92

M. Pappagallo Istituto Nazionale di Fisica Nucleare, Sezione di Ferrara

704 works36,712 citationsh-index: 94

Michael M. Bronstein Citigroup

499 works31,188 citationsh-index: 74

ReInspire: A Phase 2 Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA-Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Beth A. Drolet,Joana M. Mack,et al.

20260 citations

A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery Data

Hugo MacDermott-Opeskin,Jenke Scheen,et al.

20261 citations

Abstract PD10-07: Efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patient (pt) subset populations, including pts with PIK3CA-mutant HR+/HER2- advanced breast cancer (BC) pre-treated with fulvestrant or other SERD

C. Saura,G. Curigliano,et al.

20260 citations

Tiny Moves: Game-based Hypothesis Refinement

Agnieszka Dobrowolska,Rogier Hintzen,et al.

20260 citations

Large-scale mouse mutagenesis identifies novel genes affecting vertebral anatomy

Ximena Ibarra-Soria,Elizabeth Webb,et al.

20260 citations